Agenda

The 2009 BMT Tandem Meetings will convene February 11-15 at the Tampa Convention Center in Tampa, Fla.  Parallel conferences held in conjunction with the main scientific meeting included:

         ■  Clinical Research Professionals – February 10-12
         ■  BMT Center Administrators – February 11-12
         ■  Pediatric BMT – February 12 
         ■  BMT Pharmacists – February 13-14
         ■  Transplant Nursing – February 13-15 

In addition to the program highlights listed below, 66 speaker presentations were based on submitted abstracts.

WEDNESDAY – FEBRUARY 11

8:20 am – Opening Plenary Session   
Regulation of Alloresponses
   ■ Regulatory T Cells and Intestinal Homeostasis
         Fiona Powrie, PhD
   ■ The Role of Antigen Presenting Cells in Regulating the Graft-versus-Host Response
         Ronjon Chakraverty, MD
   ■ Adoptive Transfer of Regulatory T Cells for GVHD Prophylaxis
        Matthias Edinger, MD

10:30 am
Acute Leukemia 
   ■ All Adults with Ph- ALL Should Receive Allotransplants:  Point/Counterpoint
         Anthony H. Goldstone, MD, and Richard A. Larson, MD
   ■ Is It Time to Revisit Autologous Transplants for AML in CR1?
         Armand Keating, MD

10:30 am
Late-Effects after HCT
Stephanie J. Lee, MD, MPH, Chair

   ■ Late Effects after Autologous HCT
          Linda J. Burns, MD
   ■ Statistical Considerations in Late Effects Studies, with Examples
          Barry Storer, PhD
   ■ Psychosocial Late Effects in Survivors and Caregivers
         Michelle M. Bishop, PhD

10:30 am
Genomic and Proteomic Analysis of Hematopoietic Cell Transplant Outcome
John A. Hansen,MD, Chair

   ■ Genome-wide Association Studies of GVHD in Allogeneic Stem Cell Transplantation
          Seishi Ogawa, MD, PhD
   ■ Genomic Analysis of Transplant Toxicity, Infection and Mortality
          Jason W. Chien, MD, MS
   ■ A Proteomics Approach to Plasma Biomarkers of GVHD
         James L.M. Ferrara, MD, MD

12:15 pm  – Luncheon Symposium
Advances in Stem Cell Mobilization:  Overcoming Today’s Challenges and Examining Tomorrow’s Opportunities

(Supported by a grant from Genzyme Corporation)

4:45 pm
Oral Abstracts

6:30 pm
CIBMTR General Assembly 

6:45 pm

Mortimer M. Bortin Lecture  

   After 50 Years, Do Autotransplants Still Have A Place?
       James O. Armitage, MD 

7:30 pm
Welcome Reception

THURSDAY – FEBRUARY 12

7:15 am  – Breakfast Symposium

Controversies in the Management of Non-Hodgkin Lymphoma

(Supported by grants from Genentech BioOncology and Biogen Idec)

8:30 am
Myeloma 
   ■ Biology of Multiple Myeloma
         Irene Ghobrial, MD
   ■ Non-Transplant Regimens for Managing Multiple Myeloma
         Morie A. Gertz, MD
   ■ Autologous and Allogeneic Transplant Management for Multiple Myeloma
         Jean-Luc Harousseau, MD

10:30 am
CLL:  Biology and Treatment – Indicators for Transplantation 
   ■ Reduced-Intensity Conditioning Transplantation in CLL
         David G. Maloney, MD, PhD 
   ■ Transplantation in CLL – the Role of Monoclonal Antibodies
         Issa Khouri, MD
   ■ Going Forward:  Patient Selection for SCT for CLL
         John Gribben, MD, DSc

10:30 am
Innate Immunity
   ■ TLRs, NLRs and the Inflammasome
         Gabriel Nunez, MD
   ■ The Intestinal Barrier – Lessons from Inflammatory Bowel Disease
         Gerhard Rogler, MD
   ■ The Role of NOD2/CARD15 and Further Receptors of Innate Immunity in GVHD

      and Complications Following Allogeneic SCT
         Ernst Holler, MD

10:30 am

WBMT Key Studies
Organized by the Worldwide Group for Blood and Marrow Transplantation
Dietger Niederweiser, MD, Stella Davies, MD, PhD, Yoshihisa Kodera, MD, PhD and Machteld Oudshoorn, PhD

   ■  Overview of Unrelated Adult and Cord Blood Donation:  the WMDA Annual Survey

          Machteld Oudshoorn, PhD

   ■  Unrelated Donor Outcomes and Plans for Assessing Related Donor Outcomes:  A
       Report from the NMDP/CIBMTR
          Dennis L. Confer, MD

   ■  Related Donor Outcomes from the Japanese Registry:  The Importance of Pre-Registration
          Yoshihisa Kodera, MD, PhD

   ■  Proposal for an EBMT Donor Outcome Registry
          Joerg Halter, MD

10:30 am
Preventing Relapse after Transplantation for Pediatric ALL – Peri-transplant,

Targeted and Cellular Therapies
   ■ Pre- and Post-Transplant Chemotherapy, Antibody and Targeted Therapies
         Michael Pulsipher, MD
   ■ Minimal Residual Disease and Chimerism
        Peter Bader, MD, PhD
   ■ Peri-Transplant Cellular Therapeutics
         Laurence J.N. Cooper, MD, PhD

12:15 pm  – Luncheon Symposia

The Evolving Applications of Cellular Therapy

(Supported by a grant from Miltenyi Biotec, Inc.)

Determinants of Cord Blood Unit Quality

(Presented by New York Blood Center’s National Cord Blood Program, and supported by grants from GE Healthcare and Thermogenesis Corporation)

12:30 pm
Pediatric International Session
Sandeep Soni,MD, Carmem M.S. Bonfim, MD, and Richard P. Kadota, MD, Co-Chairs
   ■ Haplo-Identical Stem Cell Transplant Experience in China
         Xiaojun Huang, MD, PhD
   ■ Innovative Supportive Care Practices in India
         Mammen Chandy, MD 
   ■ Cord Blood Biology, Transplantation and Tissue Regeneration Applications in Israel
         Arnon Nagler, MD, MSc

1:45 pm
Transplant and Immunotherapies for Pediatric Solid Tumors 

   ■ Update on Autologous Stem Cell Transplantation for Neuroblastoma
         Stephan A. Grupp, MD, PhD
   ■ Can Antibody Therapy Replace Autologous Stem Cell Transplantation for Neuroblastoma
         Brian H. Kushner, MD
   ■ Cell and Vaccine-Based Therapies for High-Risk Pediatric Cancers
         Alan S. Wayne, MD

1:45 pm
Transplant vs. Non-Transplant for Treatment of Challenging Hematological Disorders
   ■ Paroxysmal Nocturnal Hemoglobinuria (PNH)
         Charles J. Parker, MD
   ■ Hypoplastic Myelodysplastic Syndrome/Aplastic Anemia
         Robert A. Brodsky, MD
   ■ Kostmann’s Syndrome
        John E. Levine, MD, MS

3:30 pm
Controversies of and Unique Issues in BMT Infant Leukemia
Kirk R. Schultz, MD, Chair

   ■ Juvenile Myelomonocytic Leukemia:  From Bench to Beside and Back Again
         Mignon L. Loh, MD
   ■ Infant Leukemia:  Is Transplantation the Answer?
         Steve P. Hunger, MD
   ■ Special Considerations and Complications Related to the Long-Term Outcome

      after Infant BMT
         K. Scott Baker, MD

3:30 pm
Wiskott Aldrich Syndrome
Neena Kapoor, MD, and Morton J. Cowan, MD Co-Chairs

   ■ Biology, Phenotype, Genotype of WAS
         Hans D. Ochs, MD
   ■ Update of Treatment Outcome of WAS – the U.S. Experience
         Alexandra H. Filipovich, MD
   ■ Transplant Outcome of Reduced-Intensity Conditioning for WAS
         Paul Veys, MD

4:45 pm
Oral Abstracts

6:15 pm
Poster Session I

7:30 pm  – Dinner Symposium

CMV in Hematopoietic Stem Cell Transplantation:  A Focus on Prevention and Treatment

(Supported by a grant from ViroPharma, Inc.)

FRIDAY – FEBRUARY 13

7:15 am  – Breakfast Symposium

Current Strategies in Treating Invasive Fungal Infections

(Supported by a grant from Astellas Pharma US, Inc.)

8:30 am
Regenerative Medicine
   ■ Somatic Cell Nuclear Transfer to Model Treatment of Parkinson’s Disease
         Viviane Tabar, MD
   ■ The Past and Future of Liver Transplantation:  Generation of Hepatocytes
       from Embryonic Stem Cells
         Ira J. Fox, MD
   ■ Combining Gene and Cell Therapy Using Patient-Specific Pluripotent Stem Cell
          George Q. Daley, MD, PhD

10:30 am
Oral Abstracts

12:15 pm  – Luncheon Symposium

Emerging Options in Reduced-Intensity Stem Cell Transplantation: Who, How and When?

(Supported by a grant from Otsuka America Pharmaceutical, Inc.)

4:45 pm
B Cells and Transplantation

   ■ B cell Reconstitution and Vaccine Responses After Allogeneic HCT
         Trudy N. Small, MD
   ■ Allogeneic B Cell Responses 

         David B. Miklos, MD, PhD
   ■ Autoimmune Disease and Tyrosine Kinase Inhibitors for Scleroderma
         William Robinson, MD, PhD

SATURDAY – FEBRUARY 14

7:15 am  – Breakfast Symposium

The Hematology Circle:  Optimizing Pretransplant Induction Regimens for Multiple Myeloma and Myelodysplastic Syndromes

(Supported by a grant from Celgene Corporation)

8:30 am
The Burden of Bacterial and Viral Infections in BMT
   ■ Epidemiology, Risk Factors, Spectrum of Pathogens, Emerging Resistance
         Kieren A. Marr, MD
   ■ Clinical Assessment of the Transplant Patient with Fever
         Dimitrios P. Kontoyiannis, MD, ScD
   ■ Newer Antibacterials and Antivirals:  What Is Their Role in Prophylactic,
      Empiric, Preemptive and Targeted Strategies
         Russell E. Lewis, PharmD

10:30 am
Inflammation

Pavan Reddy, MD,Chair

   ■ Inflammation and Human Disease
         Charles A. Dinarello,MD
   ■ Biology of Inflammation
          Kenneth Rock, MD
   ■ Inflammation and Bone Marrow Transplantation 

         Geoff R. Hill, MD

10:30 am
Vulnerable Transplant Patients
   ■ Transplant in the Patient with Underlying HIV Infection
         Amrita Krishnan, MD
   ■ Transplant in the Older Patient
         Sergio Giralt, MD
   ■ Transplant in the Patient with Co-morbidities and Applicability of the

      Co-Morbidity Index
          Mohammed L. Sorror, MD

10:30 am
Optimizing Cord Blood Transplantation (NMDP Session)
   ■ Optimizing Cord Blood Transplant Outcome:  A Transplant Center Perspective
         Juliet Barker
   ■ Optimizing Cord Blood Transplant Outcome:  A Registry Perspective
          Vanderson Rocha
   ■ Optimizing Cord Blood Transplant Outcome:  A Bank Perspective
          Andromachi Scaradavo

12:15 pm  – Luncheon Symposium

From Principle to Practice:  A Case-Series Workshop in Clinical Mycology

(Supported by an educational grant from Schering-Plough Corporation)

1:30 pm
Medical Directors Conference

3:00 pm
Regulatory Affairs Session

5:00 pm

E. Donnall Thomas Lecture
    Minor Histocompatibility Antigens – Their Basic Characteristics and Immune

    Functions
         Els Goulmy 

5:45 pm
ASBMT Business Meeting 

6:15 pm 
Poster Session II

7:30 pm
ASBMT President's Dinner 

SUNDAY – FEBRUARY 15

8:00 am
GVHD:  Biology and New Therapy
Daniel J. Weisdorf, MD, Chair

   ■ Biology of Acute GVHD
          Pavan Reddy, MD
   ■ New Therapy for Chronic GVHD
         Mukta Arora, MD
   ■ Immune Recovery and Reconstitution
          Crystal L. Mackall, MD

10:00 am
Oral Abstracts

12:00 noon 

“Hot Topics” (Chairmen’s Session)
James L.M. Ferrara, MD, and Mark Litzow, MD, Co-Chairs

   ■ Genetic Risk Assessment of Infectious Complications after HCT:  the Next Frontier
          Michael J. Boeckh, MD
   ■ A Potential Immunosuppressive Dendritic Cell Population in Immune Therapy and GVHD
         Husein Hadeiba, PhD
   ■ Potential Cure of HIV Infection through Transplantation of Hematopoietic Cells from a

      Donor with Inherited Absence of CCR5
          Gero Hütter, MD

1:30 pm
Adjourn